"
Team:Paris Bettencourt/Notebook/Trojan Horse/Friday 28th June.html
From 2013.igem.org
(Difference between revisions)
(Created page with "<html> <div class ="tbnote"> <h2>Trojan Horse</h2> <a href="https://2013.igem.org/Team:Paris_Bettencourt/Project/Trojan_Horse" target="_blank" class="tbnotelogo THlogo"> ASDF </a>...") |
|||
| (One intermediate revision not shown) | |||
| Line 7: | Line 7: | ||
<p><b><em> | <p><b><em> | ||
<!-- === Modify from here === --> | <!-- === Modify from here === --> | ||
| - | + | ||
<!-- === To here === --> | <!-- === To here === --> | ||
</br></em></b></p> | </br></em></b></p> | ||
<!-- === Modify from here === --> | <!-- === Modify from here === --> | ||
| - | + | ||
<p lang="en-US"> | <p lang="en-US"> | ||
sRNA design | sRNA design | ||
Latest revision as of 19:58, 3 October 2013
Trojan Horse
ASDF28th July
sRNA design
red sequences:
pACYCDuet-1 (CmR) : ATATCCAGTGATTTTTTTCTCCAT
pCOLADuet-1 (KanR) : CGTTTCCCGTTGAATATGGCTCAT
We decided that targeting only two different antibiotic resistance will be enough for a proof of concept. We give up AmpR because otherwise they might be experimental issues with AmpR that is also on phagemid litmus28i.
